Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Shanghai Ke Pharmaceutical Co. Ltd. operates within the Biotechnology & Pharmaceuticals technology area with a narrow prosecution profile. The portfolio currently shows 1 pending office action. Prosecution is handled by 1 distinct examiner across 1 distinct art unit, reflecting a centralized examination process for the company's current filings. Such a focused approach often indicates that the company is prioritizing a specific pharmaceutical candidate or a singular biotechnological method rather than a broad platform.
HIRT, ERIN E is identified as the busiest examiner for the portfolio. This individual is managing 1 busiest_examiner_pending action currently on record. Because all active prosecution is consolidated under one examiner, the company's immediate strategy depends on the specific requirements and examination history of this official. Practitioners should note that with only 1 distinct art unit involved, there is no diversification of technical review across different office sections. This concentration simplifies the management of the portfolio but increases the impact of any single examiner's decision on the company's overall patent goals.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HIRT, ERIN E | 1 | 40.3% | +23.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18258628 | STABLE LIQUID PHARMACEUTICAL COMPOSITION CONTAINING KUDING SAPONIN COMPOUND | HIRT, ERIN E | 4d overdue |
| Art Unit | Apps |
|---|---|
| 1616 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18258628 | STABLE LIQUID PHARMACEUTICAL COMPOSITION CONTAINING KUDING SAPONIN COMPOUND | HIRT, ERIN E | 1616 | §103 | Final Rejection | 4d overdue | Pending | Jun 21, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial